Company Overview and News

 
Sri Lanka’s Fortress Resorts to build Rs2.1bn 5-star hotel in Weligama

2016-12-27 lankabusinessonline
Dec 27, 2016 (LBO) – Sri Lanka’s Fortress Resorts through its fully owned subsidiary La Forteresse private limited has made an initial investment of 364 million rupees to set up a five Star Hotel in Weligama.

 
37th National Conference of Chartered Accountants to steer entrepreneurship

2016-10-11 lankabusinessonline
In helping Sri Lanka transition towards an innovation driven economy, a highly eminent panel of local and foreign speakers, including entrepreneurs of global repute will steer this month’s 37th National Conference of Chartered Accountants organised by the Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka).

 
Internationally renowned entrepreneurs to steer 37th National Conference of Chartered Accountants

2016-10-11 bizenglish.adaderana.lk
In helping Sri Lanka transition towards an innovation driven economy, a highly eminent panel of local and foreign speakers, including entrepreneurs of global repute will steer this month’s 37th National Conference of Chartered Accountants organised by the Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka).

 
Sri Lankan stocks end lower on profit-taking

2016-08-30 bizenglish.adaderana.lk
Reuters – Aug 29 Sri Lankan shares fell for a second straight session on Monday in moderate volume as investors booked profits.

 
Opinion: Central Bank’s clarification on EPF has unwittingly refuted PM and Minister of Finance?

2016-02-09 lankabusinessonline
By W.A. Wijewardena The Central Bank has issued a clarification on the Monetary Board’s alleged failure to publish the annual reports of the EPF after 2012, a concern raised by this writer in a pre...

 
Central Bank’s Clarification On EPF Has Unwittingly Refuted PM & FM ?

2016-02-07 colombotelegraph
By W.A Wijewardena – Selective response by EPF to concerns raised The Central Bank has issued a clarification, carried by Daily FT in its print edition of 1 February 2016, on the Monetary Board’s alleged failure to publish the annual reports of the EPF after 2012, a concern raised by this writer in a...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...